Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Tuesday that its fourth quarter revenues rose 54 percent year over year.

For the three months ended Dec. 31, 2019, the skin cancer diagnostics company reported revenues of $17.6 million, up from $11.4 million a year earlier, and beating the average Wall Street estimate of $11.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.